CURRICULUM VITAE for clinical trials purposes

Name: Dr Stephen Falk

Present appointment:
Consultant Clinical Oncologist at Bristol Oncology Centre
Bristol Haematology and Oncology Centre Horfield Rd Bristol BS2 8ED
Telephone number: Email address:
0117 342 2461

1983 MB ChB
1986 MRCP (UK)
1989 FRCR
1992 GMC Accreditation in Radiotherapy and Oncology
1994 MD (Liverpool)
2004 FRCP (UK)
Professional registration:
GMC No: 2820732

Research experience:
Phase I/II and III Clinical Trials
Chemotherapy and radiotherapy interactions and scheduling
DNA damage, repair and the topoisomerases
Normal tissue and tumour oxygenation

Research training: 

ICH GCP Training – 23rd April 2009

Relevant publications:

Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2008 Apr 9

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 355(1):11-20

Date: May 2009